A Drug & Medical Device Recall And/Or Safety Alert Has Been Issued: Gilenya (fingolimod): Drug Safety Communication – Safety Review of a Reported Death After the First Dose. According to the Food & Drug Administration FDA’s MedWatch:
Patients with MS should not stop taking Gilenya without talking to their healthcare professional.
For more information on the drug or medical device recall or safety alert, read the Food & Drug Administration’s FDA’s drug or medical device recall or safety alert: Gilenya (fingolimod): Drug Safety Communication – Safety Review of a Reported Death After the First Dose.
To report an adverse reaction, problem or other issue with a drug or medical device, submit a drug or medical device complaint to the government at fda.gov or MedWatch.
If you have thoughts on the drug or medical device recall or safety alert, share your drug or medical device recall or safety alert comments below.